ACUCORT AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.52 SEK | -3.70% |
|
-3.70% | +25.30% |
| Apr. 26 | AcuCort AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 16 | AcuCort AB Provides Update on Phase IV Study ZEQ001 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.
Sector
Drug Retailers
Calendar
2024-08-22
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +25.30% | 5.89M | |
| -32.09% | 15.55B | |
| -30.56% | 11.21B | |
| -30.19% | 6.23B | |
| +9.74% | 6B | |
| -10.01% | 5.89B | |
| +0.88% | 4.72B | |
| +53.60% | 4.32B | |
| -10.49% | 3.77B | |
| -12.53% | 3.4B |
- Stock Market
- Equities
- ACUC Stock
- News AcuCort AB
- Acucort Lands First Zeqmelit Order from Unimedic Pharma
